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the era has arrived in which, through the judicious 
use of available options, patients can sometimes be 
offered first-, second-, third-, and even fourth-line 
treatment options.
even more impressively, progress is still be-
ing made. Intense research is still ongoing. New 
therapeutics are on the horizon. and the roles of the 
already-introduced targeted therapies are also being 
determined, including how best to sequence targeted 
therapies and whether combined modalities will fur-
ther improve outcomes.
I am extremely grateful to the experts who ac-
cepted and took the time to contribute to this project. 
All are world leaders in the field of kidney cancer, 
and they have provided insightful and practical il-
lumination on the approaches to the management 
of this disease. Our community can be proud of the 
expertise here in canada, given that many of this 
supplement’s authors have contributed significantly to 
the research that has led to confirmation of the efficacy 
of the new therapeutic options. Many have also been 
instrumental in the development of new guidelines 
for the management of kidney cancer. Their work 
has contributed to better care for patients with kidney 
cancer in canada and around the world. I also thank 
the team at Current Oncology for their work in moving 
this project from idea to reality. Their expertise and 
professionalism were exemplary.
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It was with pleasure that I accepted to serve as editor 
of this timely supplement dedicated to kidney cancer. 
In the twenty years that I have been involved in the 
management of this disease, it has been spectacular to 
witness the evolution in treatment options. Urologic 
oncology is truly a rags-to-riches story. Through 
research and collaboration between the various spe-
cialists involved in treating kidney cancer, the disease 
has moved from having radical nephrectomy as the 
only useful treatment available, to having an exten-
sive array of options for localized disease at one end 
of the spectrum and novel therapeutic strategies for 
advanced renal cell carcinoma at the other. Kidney 
cancer has become a state-of-the-art example of 
therapy tailored to the individual patient and to the 
extent of the disease.
for the small renal mass, there is no longer any 
controversy about whether to spare the kidney and to 
remove only the area affected by cancer. Today, the 
choice is whether certain small tumours even need to 
be treated, depending on the patient’s life expectancy 
and on the tumour’s characteristics as assessed by 
imaging, pathology, and molecular criteria. In an 
explosion of effort, new ablative techniques are also 
being studied to further reduce morbidity in the treat-
ment of small renal masses.
pivotal research on the pathways related to kidney 
cancer causation and the molecular steps involved 
in its progression have led to new targeted therapies. 
In a very short time, these new agents have changed 
the landscape of oncology in a way that has rarely 
been seen in medicine. This transition has basically 
moved the field from drugs with very little activity 
in kidney cancer to five new therapeutic options 
that can prolong and improve the lives of patients. 
Because of the varying targets of the new drugs in 
the pathways that lead to proliferation and resistance, 